Personensuche
Personensuche
Es wurde 1 Person gefunden.
E-Mail
Funktionen
-
Wiss. Mitarbeiter/in und Wiss. Assistent/in, Klinik für Endokrinologie
Aktuelle Veranstaltungen
-
2024 WS
- Blockpraktikum Innere Medizin (PV)
- Pathophysiologie (WA)
- Wahlfach Klinische Endokrinologie und Diabetologie
- Endokrines Tumorzentrum am WTZ und ENETS-Center of Excellence
- Kolloquium Endokrinologie und Stoffwechsel (*)
- Neurochirurgisch-endokrinologische Konferenz / Endokrines Tumorzentrum am WTZ
- Seminare für Doktoranden in der Endokrinologie und Diabetologie
- Klinische Chemie, Laboratoriumsdiagnostik (WA)
- Klinische Visite neuroendokrine Tumoren
- Innere Medizin für Studierende im Praktischen Jahr (*)
- Klinische Visite Endokrinologie und Stoffwechsel
- Wiss. Arbeiten, Klinik für Endokrinologie, Diabetologie und Stoffwechsel
Vergangene Veranstaltungen (max. 10)
-
2024 SS
- Pathophysiologie (WA)
- Wahlfach Klinische Endokrinologie und Diabetologie
- Endokrines Tumorzentrum am WTZ und ENETS-Center of Excellence
- Blockpraktikum Innere Medizin (PV)
- Kolloquium Endokrinologie und Stoffwechsel (*)
- Neurochirurgisch-endokrinologische Konferenz / Endokrines Tumorzentrum am WTZ
- Seminare für Doktoranden in der Endokrinologie und Diabetologie
- Innere Medizin für Studierende im Praktischen Jahr (*)
- Klinische Visite neuroendokrine Tumoren
- Klinische Chemie, Laboratoriumsdiagnostik (WA)
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
Changes in tumor-to-blood ratio as a prognostic marker for progression-free survival and overall survival in neuroendocrine tumor patients undergoing PRRTIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 51 (2024) Nr. 3, S. 841 - 851Online Volltext: dx.doi.org/ (Open Access)
-
Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET StudyIn: The Oncologist Jg. 29 (2024) Nr. 5, S. e643 - e654Online Volltext: dx.doi.org/ (Open Access)
-
Dose-Response Relationship in Patients with Liver Metastases from Neuroendocrine Neoplasms Undergoing Radioembolization with ⁹⁰Y Glass MicrospheresIn: Journal of Nuclear Medicine (JNM) Jg. 65 (2024) Nr. 8, S. 1175 - 1180Online Volltext: dx.doi.org/
-
Gastrointestinale neuroendokrine Tumoren : Update 2024In: Die Innere Medizin Jg. 65 (2024) Nr. 7, S. 664 - 671Online Volltext: dx.doi.org/
-
Hormonal Hypersecretion and Pain : Rare But Not To Be ForgottenIn: The American Journal of Medicine Jg. 137 (2024) Nr. 4, S. 311 - 314Online Volltext: dx.doi.org/
-
NET-Induced Carcinoid Heart Disease Affecting Both Tricuspid and Aortic Valves Due to Patent Foramen Ovale and Right/Left Shunt : A Multi-imaging Challenge to Nuclear MedicineIn: Clinical Nuclear Medicine Jg. 49 (2024) Nr. 2, S. 157 - 159Online Volltext: dx.doi.org/
-
Stellenwert der Peptid-Radio-Rezeptor-Therapie für das Management neuroendokriner TumorenIn: Die Onkologie (2024) in pressOnline Volltext: dx.doi.org/
-
Bone Metastases in Patients with Pancreatic NETs : Prevalence and PrognosisIn: Hormone and Metabolic Research Jg. 28 (2023) Nr. 4,Online Volltext: dx.doi.org/
-
Hedinger Syndrome – Lessons Learnt : A Single-Center ExperienceIn: Journal of Cardiovascular Development and Disease Jg. 10 (2023) Nr. 10, 413Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Identification of a new prognostic score for patients with high-grade metastatic GEP-NEN treated with palliative chemotherapyIn: Journal of Cancer Research and Clinical Oncology Jg. 149 (2023) Nr. 8, S. 4315 - 4325Online Volltext: dx.doi.org/ (Open Access)
-
Outcome of immunotherapy in adrenocortical carcinoma : A retrospective cohort studyIn: European Journal of Endocrinology (EJE) Jg. 188 (2023) Nr. 6, S. 485 - 493Online Volltext: dx.doi.org/
-
Artificial Sepsis : Think Twice Before Pausing TherapyIn: The American Journal of Medicine Jg. 135 (2022) Nr. 3, S. e73 - e74Online Volltext: dx.doi.org/
-
CT-derived body composition analysis could possibly replace DXA and BIA to monitor NET-patientsIn: Scientific Reports Jg. 12 (2022) Nr. 1, 13419Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Onkologische Theranostik in der NuklearmedizinIn: Die Radiologie Jg. 62 (2022) Nr. 10, S. 875 - 884Online Volltext: dx.doi.org/
-
Onkologische Theranostik in der NuklearmedizinIn: Die Onkologie Jg. 28 (2022) Nr. 7, S. 612 - 622Online Volltext: dx.doi.org/
-
Streptozocin/5-fluorouracil chemotherapy of pancreatic neuroendocrine tumours in the era of targeted therapyIn: Endocrine Jg. 75 (2022) Nr. 1, S. 293 - 302Online Volltext: dx.doi.org/ (Open Access)
-
Treatment Approaches and Outcome of Patients with Neuroendocrine Neoplasia Grade 3 in German Real-World Clinical PracticeIn: Cancers Jg. 14 (2022) Nr. 11, 2718Online Volltext: dx.doi.org/ (Open Access)
-
⁹⁰Y Radioembolization in the Treatment of Neuroendocrine Neoplasms : Results of an International Multicenter Retrospective StudyIn: Journal of Nuclear Medicine (JNM) Jg. 63 (2022) Nr. 5, S. 679 - 685Online Volltext: dx.doi.org/ (Open Access)
-
Alpelisib in combination with everolimus ± exemestane in solid tumours : Phase Ib randomised, open-label, multicentre studyIn: European Journal of Cancer (EJC) Jg. 151 (2021) S. 49 - 62Online Volltext: dx.doi.org/
-
Correlation between contrast enhancement, standardized uptake value (SUV), and diffusion restriction (ADC) with tumor grading in patients with therapy-naive neuroendocrine neoplasms using hybrid ⁶⁸Ga-DOTATOC PET/MRIIn: European Journal of Radiology Jg. 137 (2021) S. 109588Online Volltext: dx.doi.org/
-
Multicenter Analysis of Presacral Neuroendocrine Neoplasms : Clinicopathological Characterization and Treatment Outcomes of a Rare DiseaseIn: Frontiers in Endocrinology Jg. 12 (2021) 709256Online Volltext: dx.doi.org/ (Open Access)
-
Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and AustriaIn: Experimental and Clinical Endocrinology & Diabetes Jg. 129 (2021) Nr. 07, S. 500 - 509Online Volltext: dx.doi.org/ (Open Access)
-
Sunitinib-Induced Hypothyroidism and Survival in Pancreatic Neuroendocrine TumorsIn: Hormone and Metabolic Research Jg. 53 (2021) Nr. 12, S. 794 - 800Online Volltext: dx.doi.org/ (Open Access)
-
Durable Complete Response in a Melanoma Patient With Unknown Primary, Associated With Sequential and Severe Multi-Organ Toxicity After a Single Dose of CTLA-4 Plus PD-1 Blockade : A Case ReportIn: Frontiers in Oncology Jg. 10 (2020) S. 592609Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Neuroendokrine Neoplasien des GastrointestinaltraktsIn: Der Gastroenterologe Jg. 15 (2020) Nr. 2, S. 129 - 141Online Volltext: dx.doi.org/
-
Neuroendokrine Neoplasien des VerdauungstraktsIn: Best Practice Onkologie Jg. 15 (2020) Nr. 7-8, S. 320 - 333Online Volltext: dx.doi.org/
-
Phäochromozytomatose nach Adrenalektomie : Metastasierung oder Zellverschleppung?In: Der Chirurg Jg. 91 (2020) Nr. 4, S. 345 - 353Online Volltext: dx.doi.org/
-
Textural analysis of hybrid DOTATOC-PET/MRI and its association with histological grading in patients with liver metastases from neuroendocrine tumorsIn: Nuclear Medicine Communications Jg. 41 (2020) Nr. 4, S. 363 - 369Online Volltext: dx.doi.org/
-
Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from ⁶⁸Ga-DOTATOC PET/MRI with simultaneous acquisition of apparent diffusion coefficientIn: BMC Cancer Jg. 20 (2020) Nr. 1, 326Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Hedinger syndrome : First experience and two-year follow-up in patients with carcinoid heart diseaseIn: Journal of Thoracic Disease Jg. 11 (2019) Nr. 8, S. 3234 - 3240Online Volltext: dx.doi.org/ (Open Access)
-
Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors : a phase 2, multicenter studyIn: Cancer Chemotherapy and Pharmacology Jg. 83 (2019) Nr. 2, S. 375 - 385Online Volltext: dx.doi.org/
-
Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown PrimaryIn: Neuroendocrinology Jg. 106 (2018) Nr. 3, S. 211 - 220Online Volltext: dx.doi.org/ (Open Access)
-
Neuroendokrine Neoplasien im deutschen NET-RegisterIn: Zeitschrift für Gastroenterologie Jg. 56 (2018) Nr. 10, S. 1237 - 1246Online Volltext: dx.doi.org/
-
Reply to : Appearances are often deceptiveIn: Nuklearmedizin = Nuclear Medicine Jg. 57 (2018) Nr. 4, S. 168 - 169Online Volltext: dx.doi.org/
-
Somatostatinrezeptor-PET/CT : Stand: 3/2017 - AWMF-Registernummer: 031-046In: Nuklearmedizin = Nuclear Medicine Jg. 57 (2018) Nr. 1, S. 4 - 17Online Volltext: dx.doi.org/ (Open Access)
-
The Spectrum of Thyroid Gland Pathology in Carney Complex : The Importance of Follicular CarcinomaIn: The American Journal of Surgical Pathology Jg. 42 (2018) Nr. 5, S. 587 - 594Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Combined lanreotide autogel and temozolomide in progressive neuroendocrine tumours : an interim safety analysis of the SONNET studyIn: Oncology Research and Treatment Jg. 40 (2017) Nr. Suppl. 3, S. 238 - 238Online Volltext: dx.doi.org/
-
Evaluation of 68Ga-DOTATOC PET/MRI for whole-body staging of neuroendocrine tumours in comparison with 68Ga-DOTATOC PET/CTIn: European Radiology Jg. 27 (2017) Nr. 10, S. 4091 - 4099Online Volltext: dx.doi.org/
-
Everolimus (EVE) in Advanced, Nonfunctional, Well-differentiated Neuroendocrine Tumors (NET) of Gastrointestinal (GI) or Lung Origin : Second Interim Overall Survival (OS) Results From the RADIANT-4 StudyIn: Pancreas Jg. 46 (2017) Nr. 3, S. 437 - 438Online Volltext: dx.doi.org/
-
Everolimus for Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Gastrointestinal (GI) Tract : Efficacy and Safety from a RADIANT-4 Subgroup AnalysisIn: Pancreas Jg. 46 (2017) Nr. 3, S. 436 - 436Online Volltext: dx.doi.org/
-
Extension study to the open-label, multi-center, expanded access study of everolimus in patients with advanced neuroendocrine tumorsIn: Oncology Research and Treatment Jg. 40 (2017) Nr. Suppl. 3, S. 237 - 238Online Volltext: dx.doi.org/
-
Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4trial) : a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialIn: The Lancet Oncology Jg. 18 (2017) Nr. 10, S. 1411 - 1422Online Volltext: dx.doi.org/
-
Impact of season and different vitamin D thresholds on prevalence of vitamin D deficiency in epidemiological cohorts : a note of cautionIn: Endocrine Jg. 56 (2017) Nr. 3, S. 658 - 666Online Volltext: dx.doi.org/
-
Results from a Phase 2, Open-Label, Multicenter, Randomized Study of the Novel, Octreotide (Oct) Subcutaneous (SC) Depot Formulation in Patients with Functioning Neuroendocrine Tumors (NETs) and Acromegaly Previously Treated with Long-Acting OctreotideIn: Neuroendocrinology Jg. 105 (2017) Nr. Suppl. 1, S. 203 - 203Online Volltext: dx.doi.org/
-
A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine TumoursIn: Anticancer Research Jg. 36 (2016) Nr. 2, S. 713 - 719
-
A Piece of the Puzzle : The Bone Health Index of the BoneXpert Software Reflects Cortical Bone Mineral Density in Pediatric and Adolescent PatientsIn: PLoS ONE Jg. 11 (2016) Nr. 3, S. e0151936Online Volltext: dx.doi.org/ (Open Access)
-
Efficacy and safety of everolimus in advanced, progressive, nonfunctional neuroendocrine tumors (NET) of the gastrointestinal (GI) tract and unknown primary : A subgroup analysis of the phase III RADIANT-4 trialIn: Journal of Clinical Oncology (JCO) Jg. 34 (2016) Nr. Suppl. 4, S. 315Online Volltext: dx.doi.org/
-
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4) : a randomised, placebo-controlled, phase 3 studyIn: Lancet Jg. 387 (2016) Nr. 10022, S. 968 - 977Online Volltext: dx.doi.org/
-
Neuroendokrine Neoplasien des PankreasIn: Der Radiologe Jg. 56 (2016) Nr. 4, S. 348 - 354Online Volltext: dx.doi.org/
-
5LBA Everolimus in advanced nonfunctional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) origin : Efficacy and safety results from the placebo-controlled, double-blind, multicenter, Phase 3 RADIANT-4 studyIn: European Journal of Cancer (EJC) Jg. 51 (2015) Nr. Suppl. 3, S. 709 - S710Online Volltext: dx.doi.org/
-
Artificial Hyperparathyroidism : Think Twice Before Taking Your Blood SampleIn: The American Journal of Medicine Jg. 128 (2015) Nr. 12, S. 21 - 22Online Volltext: dx.doi.org/
-
Baseline demographics of patients from the randomized, placebo-controlled, double-blind, phase III RADIANT-4 study of everolimus in nonfunctional gastrointestinal (GI) or lung neuroendocrine tumors (NET)In: Journal of Clinical Oncology (JCO) Jg. 33 (2015) Nr. Suppl. 3, S. 276Online Volltext: dx.doi.org/
-
Clinical Outcome of Everolimus Treatment of Advanced Neuroendocrine Neoplasms : Real-Life Data from the German NET-RegisterIn: Neuroendocrinology Jg. 102 (2015) Nr. 1-2, S. 132Online Volltext: dx.doi.org/
-
Einseitige Aderhautfalten als Folge ausgedehnter skleraler Verkalkungen durch alimentär induzierte HyperkalzämieIn: Klinische Monatsblätter für Augenheilkunde Jg. 232 (2015) Nr. 9, S. 1099 - 1100Online Volltext: dx.doi.org/
-
Neuroendokrine Neoplasien der MammaIn: Der Pathologe Jg. 36 (2015) Nr. 3, S. 261 - 270Online Volltext: dx.doi.org/
-
Peptidrezeptor-Radionuklidtherapie Somatostatinrezeptor-exprimierender TumoreIn: Nuklearmedizin = Nuclear Medicine Jg. 54 (2015) Nr. 1, S. 1 - 11Online Volltext: dx.doi.org/
-
Carney complex : Coincidence of ACTH and GH excessIn: Experimental and Clinical Endocrinology & Diabetes Jg. 122 (2014) Nr. 3, OP5_26Online Volltext: dx.doi.org/
-
Neuroendokrine Neoplasien des distalen Jejunums und IleumsIn: Der Pathologe Jg. 35 (2014) Nr. 3, S. 283 - 294Online Volltext: dx.doi.org/
-
Streptozotocin-based chemotherapy in pNET : A single-centre experienceIn: Experimental and Clinical Endocrinology & Diabetes Jg. 122 (2014) Nr. 3, S. P108Online Volltext: dx.doi.org/
-
Can a homecare service improve the Quality of Life (QoL) and treatment satisfaction for patients (pts) while maintaining the remisson rate during Sandostatin® LAR® treatment?In: Experimental and Clinical Endocrinology & Diabetes Jg. 121 (2013) S. P70Online Volltext: dx.doi.org/
-
Fulminant progressive thyroid cyst with tracheal compression - a case reportIn: Experimental and Clinical Endocrinology & Diabetes Jg. 121 (2013) Nr. 3, S. P23Online Volltext: dx.doi.org/
-
Immune-related hypophysitis in three patients with metastatic melanoma undergoing Ipilimumab treatmentIn: Experimental and Clinical Endocrinology & Diabetes Jg. 121 (2013) S. P10Online Volltext: dx.doi.org/
-
Malignant Prolactinoma - a therapeutic challengeIn: Experimental and Clinical Endocrinology & Diabetes Jg. 121 (2013)Online Volltext: dx.doi.org/
-
Prevalence of thyroid dysfunction and age dependency of TSH in a population-based study : Results from the Heinz Nixdorf Recall Study (HNR)In: Experimental and Clinical Endocrinology & Diabetes Jg. 121 (2013) Nr. 3, S. P16Online Volltext: dx.doi.org/
-
Prevalence of vitamin D deficiency in a population-based study : Results from the Heinz Nixdorf Recall StudyIn: Experimental and Clinical Endocrinology & Diabetes Jg. 121 (2013) Nr. 3, OP10_64Online Volltext: dx.doi.org/
-
Sunitinib in pancreatic neuroendocrine tumoursIn: Experimental and Clinical Endocrinology & Diabetes Jg. 121 (2013) S. P60Online Volltext: dx.doi.org/
-
Assay-Abhängigkeit der Calcitonin- Zielbereiche für „biochemisch geheilte“ Patienten mit medullärem SchilddrüsenkarzinomIn: Nuklearmedizin = Nuclear Medicine Jg. 51 (2012) Nr. 4, S. 125 - 132Online Volltext: dx.doi.org/
-
Impact of various national and international Limits for Vitamin D DEficiency in a population-based StudyIn: Das Gesundheitswesen Jg. 74 (2012) Nr. 8-9, S. 587 - 587
-
Y-90-DOTATOC PET/CT for acquisition of biodistribution following peptide receptor radionuclide therapyIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 39 (2012) Nr. Suppl. 2, S. S331 - S332
-
68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in Functional Imaging of Neuroendocrine TumorsIn: Journal of Nuclear Medicine Jg. 52 (2011) Nr. 12, S. 1864 - 1870Online Volltext: dx.doi.org/
-
68Ga-DOTATOC vs. 68Ga-DOTATATE PET/CT in functional imaging of Neuroendocrine TumoursIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 38 (2011) Nr. Suppl. 2, S. 97 - S98
-
Chemotherapy in Patients with Progressive, Undifferentiated Neuroendocrine Tumors : A Single-Center ExperienceIn: Hormone and Metabolic Research Jg. 43 (2011) Nr. 12, S. 838 - 843Online Volltext: dx.doi.org/
-
Is minimally invasive, video-assisted thyroidectomy feasible in Graves' disease?In: Surgery Jg. 149 (2011) Nr. 4, S. 556 - 560Online Volltext: dx.doi.org/
-
Treatment of Advanced Medullary Thyroid Carcinoma with a Combination of Cyclophosphamide, Vincristine, and Dacarbazine : a Single-Center ExperienceIn: Experimental and Clinical Endocrinology & Diabetes Jg. 119 (2011) Nr. 9, S. 540 - 543Online Volltext: dx.doi.org/
-
Apoptotic markers indicate nonalcoholic steatohepatitis in polycystic ovary syndromeIn: The Journal of Clinical Endocrinology & Metabolism (JCEM) Jg. 95 (2010) Nr. 1, S. 343 - 348Online Volltext: dx.doi.org/
-
Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly : Comparison with matched data from the general population and the effect of disease controlIn: The Journal of Clinical Endocrinology & Metabolism (JCEM) Jg. 95 (2010) Nr. 8, S. 3648 - 3656Online Volltext: dx.doi.org/
-
Diagnostic utility of the glucagon stimulation test in comparison to the insulin tolerance test in patients following pituitary surgeryIn: European Journal of Endocrinology (EJE) Jg. 162 (2010) Nr. 3, S. 477 - 482Online Volltext: dx.doi.org/
-
Large effects on body mass index and insulin resistance of fat mass and obesity associated gene (FTO) variants in patients with polycystic ovary syndrome (PCOS)In: BMC Medical Genetics Jg. 11 (2010) 12Online Volltext: dx.doi.org/ (Open Access)
-
Posterior Retroperitoneoscopic Adrenalectomy for Clinical and Subclinical Cushing’s SyndromeIn: World Journal of Surgery Jg. 34 (2010) Nr. 6, S. 1391 - 1397Online Volltext: dx.doi.org/
-
Recovery of pituitary function in the late-postoperative phase after pituitary surgery : Results of dynamic testing in patients with pituitary disease by insulin tolerance test 3 and 12 months after surgeryIn: European Journal of Endocrinology (EJE) Jg. 162 (2010) Nr. 5, S. 853 - 859Online Volltext: dx.doi.org/
-
The Effect of Pegvisomant on Cardiovascular Risk in Patients with Active Acromegaly in Comparison to Matched Data from the General Population
The Endocrine Society’s 92nd Annual Meeting & Expo, 1 June 2010,In: Endocrine Reviews Jg. 31 (2010) Nr. 3, Suppl. 1, S. 857, OR16-6Online Volltext: dx.doi.org/ -
Androgenproduzierender Leydig-Zell-Tumor des Ovars als Ursache von Hirsutismus bei einer postmenopausalen FrauIn: Medizinische Klinik Jg. 102 (2007) Nr. 3, S. 259 - 262Online Volltext: dx.doi.org/
-
166Holmium-SIRT after PRRT (HEPAR PLuS) versus PRRT-only in Patients with Metastatic Neuroendocrine Tumors: a Propensity-score Matched Analysis
Annual Congress of the European Association of Nuclear Medicine, 9-13 September 2023 Vienna, Austria,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 50 (2023) Nr. 1 supplement, S. S379Online Volltext: dx.doi.org/ (Open Access) -
Prognostic value of the post-treatment 177Lu-DOTATOC scintigraphy in NET patients undergoing PRRT
Annual Congress of the European Association of Nuclear Medicine, 9-13 September 2023, Vienna, Austria,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 50 (2023) Nr. 1 supplement, S. S134Online Volltext: dx.doi.org/ (Open Access) -
Changes in Tumor-Blood Ratio as a prognostic marker for progression-free survival and overall survival in neuroendocrine tumor patients undergoing PRRT
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022, Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) Nr. Supplement 1, S. S80Online Volltext: dx.doi.org/ (Open Access) -
Treatment outcomes of patients with G3 neuroendocrine neoplasms Data from the German NET Registry
18th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease 25 – 27 February 2021,In: Journal of Neuroendocrinology Jg. 33 (2021) Nr. S1, S. 72Online Volltext: dx.doi.org/ (Open Access) -
Disease Control in Progressive Pancreatic and Intestinal Neuroendocrine Tumors by Combined Treatment with Lanreotide Autogel and Temozolomide : The SONNET Study
15th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease ; March 7–9, 2018, Barcelona,In: Neuroendocrinology Jg. 106 (2018) Nr. Suppl. 1, S. 202Online Volltext: dx.doi.org/ (Open Access) -
Disease control in progressive pancreatic and intestinal neuroendocrine tumours with combined treatment with lanreotide Autogel and temozolomide : the SONNET study
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 28. September - 2. Oktober 2018, Wien,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 4, S. 263Online Volltext: dx.doi.org/ (Open Access) -
Long-term Survival(LTS) and Survivorship Program(SS-P) of Lung Cancer(LC) Patients(Pts). Investigations(Invest) on LT-toxicities(Tox) and late morbidities(Morb)
33. Deutscher Krebskongress - Perspektiven verändern Krebs - Krebs verändert Perspektiven. Diagnose - Therapie - (Über-)Leben ; 21.-24. Februar 2018, Berlin,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 1, S. 108Online Volltext: dx.doi.org/ (Open Access) -
Combination of Lanreotide Autogel and Temozolomide in Patients with Progressive Gastro-Entero-Pancreatic Neuroendocrine Tumours (GEP-NET) - A Pilot-StudyIn: Neuroendocrinology Jg. 103 (2016) Nr. Suppl. 1, S. 75 - 75Online Volltext: dx.doi.org/
-
Everolimus for Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Gastrointestinal (GI) Tract : Efficacy and Safety from a RADIANT-4 Subgroup AnalysisIn: Neuroendocrinology Jg. 103 (2016) Nr. Suppl. 1, S. 85 - 85Online Volltext: dx.doi.org/
-
Secondary analysis from the RADIANT-4 trial : Impact of prior Somatostatin Analogue (SSA) use on progression-free survival in patients with advanced nonfunctional Neuroendocrine Tumors (NET) of lung or Gastrointestinal (GI) originIn: Oncology Research and Treatment Jg. 39 (2016) Nr. Suppl. 3, S. 281 - 282Online Volltext: dx.doi.org/
-
Secondary analysis from the phase 3 RADIANT-4 trial : Evaluating the impact of prior chemotherapy (CTx) on progression-free survival in patients with advanced, nonfunctional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) originIn: Oncology Research and Treatment Jg. 39 (2016) Nr. Suppl. 3, S. 281Online Volltext: dx.doi.org/
-
Pre-treatment intensity of DOTATOC uptake for prediction of response to selective intravascular radionuclide therapy
28th Annual EANM Congress of the European Association of Nuclear Medicine, 10-14 October 2015, Hamburg, Germany,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 42 (2015) Nr. Suppl. 1, S. S8 - S9Online Volltext: dx.doi.org/ -
Health-related Quality-of-Life in everolimus-treated patients with advanced neuroendocrine tumors : results from an open-label, phase IIIb, multicenter, expanded access program (EVIDENT)
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 10.-14. Oktober 2014, Hamburg,In: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 5, S. 152Online Volltext: dx.doi.org/ -
Prevalence of thyroid dysfunction and age dependency of TSH in a population-based study : Results from the Heinz Nixdorf Recall StudyIn: Der Internist Jg. 54 (2013) Nr. Suppl. 1, 119. Kongress der Deutschen Gesellschaft für Innere Medizin e.V., 06. - 09. April 2013, Wiesbaden, S. 18 - 19Online Volltext: dx.doi.org/
-
Chemotherapy in the Treatment of Progressive, Undifferentiated Neuroendocrine Carcinomas : A Single-Center Experience
7th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease March 11–12, 2010 Berlin, Germany,In: Neuroendocrinology Jg. 92 (2010) Nr. 1, S. 27Online Volltext: dx.doi.org/ -
Combined medical therapy, nuclear medicine therapy and other therapies in metastatic neuroendocrine tumorIn: Nuclear Medicine and Molecular Imaging: Volume 4: Nuclear Medicine Therapy / Signore, Alberto / Sathekge, Mike; Luster, Markus (Hrsg.) 2022, S. 145 - 156Online Volltext: dx.doi.org/
-
Differential Uptake of 68Ga-DOTATOC and 68Ga-DOTATATE in PET/CT of Gastroenteropancreatic Neuroendocrine TumorsIn: Theranostics, Gallium-68, and Other Radionuclides: A Pathway to Personalized Diagnosis and Treatment / Baum, Richard P.; Rösch, Frank (Hrsg.) 2013, S. 353 - 371Online Volltext: dx.doi.org/
-
Lack of Somatostatin Receptor Subtype-2 (SSTR2) in the Normal Human Thyroid Gland at Protein Level : Apparent Discrepancy of Immunohistochemistry and Gender-Specific Uptake of 68Ga-DOTATOC?
27th Annual Congress of the European Association of Nuclear Medicine, October 18–22, 2014, Gothenburg, Sweden,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 41 (2014) Nr. Suppl. 2, S. S411Online Volltext: dx.doi.org/